Objectives: To estimate prognosis by viral subtype in HIV-1-infected individuals from start of
antiretroviral therapy (ART) and after viral failure. Design: Collaborative analysis of data from …

Background HIV cohort collaborations, which pool data from diverse patient cohorts, have
provided key insights into outcomes of antiretroviral therapy (ART). However, the extent of …

Background. Patterns of cause-specific mortality in individuals infected with human
immunodeficiency virus type 1 (HIV-1) are changing dramatically in the era of antiretroviral …

Introduction Model‐based estimates of key HIV indicators depend on past epidemic trends
that are derived based on assumptions about HIV disease progression and mortality in the …

Introduction HIV-1 subtypes have been associated with less favourable clinical profiles,
differences in disease progression and higher risk of neurocognitive deficit. In this study we …

Objectives To report 10-year outcomes of virological and immunological treatment failure
rates and risk factors. Design Prospective cohort study. Setting Shenzhen, China …

Background. We examined specific causes of mortality in human immunodeficiency virus
type 1 (HIV-1)—infected patients who initiated antiretroviral therapy (ART) in Europe and …

Abstract (See the Editorial Commentary by Gatell, on pages 1153–5.) Background.
Antiretroviral compounds have been predominantly studied in human immunodeficiency …

Objective: The influence of viral subtype on the natural history of HIV is unclear and
confounded by socioeconomic and host factors that vary between groups harboring different …

To assess whether human immunodeficiency virus type 1 (HIV-1) genotype influences
baseline CD4+ T lymphocyte (CD4+) cell count and mortality of patients. The study was …